Shares of Biogen Stock Surge on Back of Beat-and-Raise

The stock gapped higher in June after posting positive results from its Alzheimer's drug trial

Managing Editor
Jul 24, 2018 at 9:28 AM
facebook twitter linkedin

Shares of Biogen Inc (NASDAQ:BIIB) are soaring in early trading after the company this morning posted a second-quarter earnings beat and raised its full-year outlook. The pharmaceutical concern benefited from strong sales of its muscle disease drug, Spinraza, which actually doubled during the quarter. BIIB is up 6.8% at $382.50, at last check.

Looking at the charts, Biogen stock gapped higher earlier this month thanks to a Alzheimer's drug trial breakthrough, reclaiming positive year-to-date territory following a sharp downtrend from its late-January two-year high of $370.57. The stock now sports a year-to-date gain north of 20%.

Digging into options data, short-term traders are more call-skewed than usual, with BIIB's Schaeffer's put/call open interest ratio (SOIR) of 0.74 ranking in the 11th annual percentile. This indicates that near-term call open interest outweighs put open interest by a wider-than-usual margin.

Lastly, analyst sentiment has been heavily optimistic. Seventeen of 24 firms in coverage sport "buy" or "strong buy" recommendations, though Biogen stock's average 12-month price target of $369.42 comes in at a discount to current levels.


Minimize Risk While Maximizing Profits

There is no options strategy like this one, which consistently minimizes risk while maintaining maximum profits. Perfect for traders looking for ways to control risk, reduce losses, and increase the likelihood of success when trading calls and puts. The Schaeffer’s team has over 41 years of options trading success targeting +100% gains on every trade. Rest assured your losses are effectively limited to your initial cost at the time of making your move! Don't waste another second... join us right now before the next trade is released! 



Special Offers from Schaeffer's Trading Partners